|Day Low/High||89.62 / 90.46|
|52 Wk Low/High||72.05 / 92.64|
Merck CEO Ken Frazier is leaving Trump's business council.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending stocks.
Merck , said today that its board of directors authorized a quarterly dividend of 47 cents
Stocks hold losses as a selloff in Snap pulls the rest of the tech sector lower.
The price momentum and money flow indicators of the drug maker are in positive alignment.
These three big stocks are teetering on the edge of breakout territory to start the month.
"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as I have I might be trading some of the earnings reports that will be released ...
Trump suggested he could split their consumer businesses from investment operations
Biotech investors should keep a close eye on the progress in this huge potential market.
"Doug Kass wrote an article today about how he fears the lack of fear in this market. I agree with Doug that lack of fear is an issue, but it goes further than that. What this market has missed for quite some time is strong emotion. There may not be...
'These companies are all assessing the Trump effect,' Cramer said.
It's pretty normal to have profit-taking after such a strong first quarter.
We know that we are in the era when index managers are ascendant.
Get your plan in place, but understand that the Republic is not in jeopardy.
"I would describe today's market action as "benign." And that applies to almost every asset class." -- Kass Diary 104 trading sessions without a one percent drop in the indices. "Don't Think the Machines Could Turn to Selling? You've Forgotten 1987....
Healthcare stocks had a heckuva four-year period of over-performance that ended in the summer of 2015. Since then the Health Care Select Sector SPDR ETF (40% pharma and 15% biotech) has had a series of trading-range moves as sector prices lagged. La...
Stocks were under pressure again after Donald Trump made vague promises to lower drug prices.
In a 24-week trial of 22 patients, OncoSec saw a 41% response rate
Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is keeping an eye on quarterly results from Valeant Pharmaceuticals on Tuesday.